Analysis of the relationship between age and treatment response in migraine.
In migraine, headache severity varies with age. As a consequence, the effectiveness of medication may also depend on a patient's age. The purpose of this study was to assess the combined effect of age and drug treatment on headache characteristics. Using data from clinical trials of sumatriptan in adolescents and adults, we show how the interaction between age and drug exposure can be parameterised as a covariate on a Markov model that describes the decline of headache severity over three clinically defined stages (no relief, relief and pain-free status). The model explains important clinical observations: (i) the rates at which the pain relief and pain-free status were attained were found to be inversely related to age; (ii) in placebo-treated patients, the mean transit time from 'no relief' to 'relief' is 3 h for young adolescents and increases to 6 h for patients aged >or= 30 years; and (iii) sumatriptan reduces the transit time to 2 h, irrespective of age. These findings indicate that the therapeutic gain over placebo increases with age. Prospective studies of antimigraine drugs should take this relationship into account when extrapolating efficacy data from adults to adolescents.
Maas
H J
HJ
Division of Pharmacology, Leiden/Amsterdam Center for Drug Research, the Netherlands.
Danhof
M
M
Della Pasqua
O E
OE
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D002986:Clinical Trials as Topic; D006801:Humans; D008390:Markov Chains; D008881:Migraine Disorders / Q000188:drug therapy*; D015990:Placebo Effect; D010919:Placebos; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D018170:Sumatriptan / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
D010919:Placebos; D017366:Serotonin Receptor Agonists; D018170:Sumatriptan